NCT01083966 - Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Vestibular Schwannoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2027

Conditions

Vestibular Schwannoma

Interventions

DRUG

Bevacizumab (Avastin)

"Super-Selective Intraarterial Intracranial Infusion of Bevacizumab in Vestibular Schwannoma~This phase I clinical research trial will test the hypothesis that Bevacizumab can be safely used by direct intracranial superselective intraarterial infusion up to a dose of 10mg/kg to ultimately enhance survival and hearing function of patients with VS"

Trial Locations (1)

10075

Lenox Hill Brain Tumor Center, New York